Cheryl H. Waters, MD
Cheryl Waters MD FRCP(C), holds bachelors and masters degrees in Pharmacology from the University of Toronto, where she studied dopamine receptor function with Philip Seeman. She completed medical school at University of Toronto, an internship at University of Chicago, and returned to Toronto for Internal Medicine, Neurology and a fellowship in Clinical Pharmacology. She moved to California and developed the Movement Disorder Program at the University of Southern California. Dr. Waters then moved to New York to take on her current position as Chief of Clinical Practice and Services in the Division of Movement Disorders. She has been involved in research on the genetics of Parkinson's disease and the treatment of this disorder. She has authored numerous articles and book chapters and a book in its seventh edition: Diagnosis and Management of Parkinson's Disease. She has been an investigator in numerous studies involving a variety of new medical and surgical treatments. She is the first to hold the Albert B. and Judith L. Glickman Chair in Neurology.
Areas of Expertise / Conditions Treated
- Movement Disorder
- Parkinson's Disease
- Albert B. and Judith L. Glickman Professor of Neurology at CUMC
- NewYork-Presbyterian / Columbia University Irving Medical Center
Schedule an Appointment
Virtual Visits allow you to connect with your provider from the comfort, convenience, and safety of your own home.
Credentials & Experience
Education & Training
- University of Toronto Faculty of Medicine
- Residency: University of Toronto Hospitals
- Fellowship: University of Toronto Hospitals
Espay AJ, Pagan FL, MD,Walter BL, MD; Morgan JC, Elmer LW,. Waters CH,et al. Optimizing extended-release carbidopa/levodopa in Parkinson's disease: Consensus on conversion from standard therapy. Neurology Clinical Practice 2017;7:1-8
Chan RB, Perotte AJ, Zhou B, Liong C, Shorr EJ, Marder KS, Kang UJ, Waters CH, Levy OA, Xu Y, Shim HB. Elevated GM3 plasma concentration in idiopathic Parkinson's disease: A lipidomic analysis. PloS one. 2017 Feb 17;12(2):e0172348.
Sklerov, M; Waters, C. Understanding Multiple System Atrophy: Could Genetics Lead the Way? US Neurology, 2016;12(2):110-2.
Alcalay R.N, Levy OA, Wolf P, Oliva P, Zhang, X.K, Waters,CH, et al. (2016). SCARB2 variants and glucocerebrosidase activity in Parkinson's disease. npj Parkinson's Disease, 2, 16004.
Alcalay RN, Levy OA, Waters CH et al, Glucocerebrosidase activity in Parkinson's disease with and without GBA mutations. Brain Jun 2015, DOI: 10.1093/brain/awv179
Waters CH, Nausieda P, Dzyak L, et al, Long-Term Treatment with Extended-Release Carbidopa-Levodopa (IPX066) in Early and Advanced Parkinson's Disease: A 9-Month Open-Label Extension Trial. CNS Drugs 2015:29:4: 341-350.
Gan-Or Z, Alcalay RN, Bar-Shira A, Leblond C, Postuma RB,Ben-Shachar S, Waters C, et al. Genetic markers of Restless Legs Syndrome in Parkinson Disease. Park Related Disordshttp://dx.doi.org/10.1016/j.parkreldis.2015.03.010
Sharp ME , Caccappolo E , Mejia-Santana H , Tang M -X , Rosado L , Orbe Reilly M , Ruiz D , Louis ED , Comella C, Nance M , Bressman S , Scott WK , Tanner C , Mickel , Waters C et al The relationship between Obsessive-Compulsive symptoms and PARKIN genotype: The CORE-PD study Mov Disord. 2015 Feb;30(2):278-83. doi: 10.1002/mds.26065
Waters, Cheryl H: Diagnosis and Management of Parkinson's Disease. Professional Communications Inc., Caddo, Oklahoma. 7th edition, 2014.
Kestenbaum M, Waters C. Magnetic Resonance Imaging and Dopamine Transporter Single Photon Emission Tomography in Parkinson's Disease-When Should We Use Them? US Neurology,2014;10(2):90-1
Marek K1, Seibyl J, Eberly S, Oakes D, Shoulson I, Lang AE, Hyson C, Jennings D; For The Parkinson Study Group PRECEPT Investigators. Longitudinal follow-up of SWEDD subjects in the PRECEPT Study Neurology 2014;82:1791-1797.
Alcalay RN, Dinur T, Quinn T, Sakanaka K, Levy OA, Waters C, Fahn S, Dorovski T, Chung WK, Pauciulo M, Nichols W, Rana HQ, Balwani M, Bier L, Elstein D, Zimran A. Comparison of Parkinson Risk in Ashkenazi Jewish Gaucher Patients and GBA Heterozygotes 2014 Jun;71(6):752-7. doi: 10.1001/jamaneurol.2014.313.
Waters C. The development of the rotigotine transdermal patch: a historical perspective. Neurol Clin. 2013 Aug;31(3 Suppl):S37-50. doi: 10.1016/j.ncl.2013.04.012. Epub 2013 Jun 14.
Arkadir D, Greene PE, Waters CH, Moskowitz CB, Sharp ME. Applause sign in clinically overlapping diseases: a case of TDP-43 proteinopathy. Park Relat Disord2013 Aug;19(8):774-5. doi: 10.1016/j.parkreldis.2013.04.016. Epub 2013 May 13.
Alcalay RN, Caccappolo E , Mejia-Santana H , Tang M -X , Rosado L , Orbe Reilly M,Ruiz D , Louis ED , Comella C , Nance M , Bressman S , Scott WK , Tanner C , Mickel S , Waters C et al, Cognitive and motor function in long duration PARKIN PD. Arch Neurol 2013 Nov 4. doi: 10.1001
Alcalay RN, Mirelman A, Saunders-Pullman R, Tang MX, Mejia Santana H, Raymond D, Roos E, Orbe-Reilly M, Gurevich T, Bar Shira A, Gana Weisz M, Yasinovsky K, Zalis M, Thaler A, Deik A, Barrett MJ, Cabassa J, Groves M, Hunt AL, Lubarr N, San Luciano M, Miravite J, Palmese C, Sachdev R, Sarva H, Severt L, Shanker V, Swan MC, Soto-Valencia J, Johannes B, Ortega R, Fahn S, Cote L, Waters C et al. Parkinson Disease Phenotype in Ashkenazi Jews with and without LRRK2 G2019S mutations. Mov Disord. 10/15/2013.
Hauser RA, Hsu A, Kell S, et al. Extended-release carbidopa - levodopa (IPX066) compared with immediate - release carbidopa - levodopa in patients with Parkinson's disease and motor fluctuations: a phase 3 randomized, double-blind trial. The Lancet Neurology 2013;12: 346-356.
Liu X, Cheng R, Ye X, Verbitsky M, Kisselev S, Mejia-Santana H, Louis ED, Cote LJ, Andrews H, Waters C, Ford B, Fahn S, Marder K, Lee JH and Clark LN. Increased rate of Sporadic and Recurrent Rare Genic Copy Number Variants in Parkinson's Disease among Ashkenazi Jews. Molecular Genetics and Genomic Medicine. 2013. 1(3), 142-154.
Sakanaka K, Waters CH, Levy OA, Louis ED, Chung WK, Marder KS, Alcalay RN. Knowledge of and interest in genetic results among Parkinson disease patients and caregivers. J Genet Counsel 2013. Doi 10.1007/s10897-013-9618-y
Waters C, Smolowitz J: Sexual Dysfunction. In: Parkinson's disease: second edition, CRC press, Pfeiffer R, Wszolek Z, Ebadi M,Eds, 2013, pp 343-352.
Waters CH and Smolowitz J: Impaired Sexual Function. In: Parkinson's Disease and Nonmotor Dysfunction. Pfeiffer RF, Bodis-Wollner I (eds) Humana Press (Springer Science, New York) 2013, pp 173-187.
Waters C, The Development of the Rotigotine Transdermal Patch: A Historical Perspective Neurologic Clinics 2013 Aug;31(3 Suppl):S37-50. doi: 10.1016/j.ncl.2013.04.012. Epub 2013 Jun 14.
Wright, B Waters CH. Continuous Dopaminergic Delivery to Minimize Motor Complications in Parkinson's Disease. Expert reviews of Neurotherapeutics2013 Jun;13(6):71929. doi: 10.1586/ern.13.47.